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Abstract
Background: Early satiety (ES) and postprandial fullness (PPF) are often present in 
gastroparesis, but the importance of these symptoms in gastroparesis has not been 
well- described. The aims were: (i) Characterize ES and PPF in patients with gastropa-
resis. (ii) Assess relationships of ES and PPF with etiology of gastroparesis, quality of 
life, body weight, gastric emptying, and water load testing.
Methods: Gastroparetic patients filled out questionnaires assessing symptoms (PAGI- 
SYM) and quality of life (PAGI- QOL, SF- 36v2). Patients underwent gastric emptying 
scintigraphy and water load testing.
Key Results: 198 patients with gastroparesis (134 IG, 64 DG) were evaluated. Early 
satiety was severe or very severe in 50% of patients. Postprandial fullness was severe 
or very severe in 60% of patients. Severity scores for ES and PPF were similar between 
idiopathic and diabetic gastroparesis. Increasing severity of ES and PPF were associ-
ated with other gastroparesis symptoms including nausea/vomiting, satiety/early full-
ness, bloating, and upper abdominal pain and GERD subscores. Increasing severity of 
ES and PPF were associated with increasing gastroparesis severity, decreased BMI, 
decreased quality of life from PAGI- QOL and SF- 36 physical health. Increasing sever-
ity of ES and PPF were associated with increasing gastric retention of a solid meal and 
decreased volume during water load test.
Conclusions & Inferences: Early satiety and PPF are commonly severe symptoms in 
both diabetic and idiopathic gastroparesis. Early satiety and PPF severity are associ-
ated with other gastroparesis symptom severities, body weight, quality of life, gastric 
emptying, and water load testing. Thus, ES and PPF are important symptoms charac-
terizing gastroparesis. ClinicalTrials.gov number: NCT NCT01696747.
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1  | INTRODUCTION
Symptoms of gastroparesis can be varied, but classically include 
nausea and vomiting.1 Early satiety (ES) and postprandial fullness 
(PPF) can also be present. Early satiety and PPF have been re-
ported to be present in 54- 60% of patients with gastroparesis.2,3 
The Gastroparesis Cardinal Symptom Index- Daily Diary (GCSI- DD) 
developed through patient interviews and input from the Federal 
Drug Administration (FDA) contains five symptoms: nausea, vomit-
ing, ES, PPF, and abdominal pain.4, 5 Both ES and PPF were included 
in this patient reported outcome. They appear to capture different 
pathophysiologic aspects of gastroparesis: ES due to impaired proxi-
mal gastric (fundic) function and PPF due to impaired distal gastric 
(antral) function.
Normally with solid food ingestion, the upper stomach relaxes, al-
lowing the proximal stomach to accommodate the ingested meal. This 
is followed by a progressively tonic contraction to deliver food into 
the distal stomach.6–8 In the antrum, regular peristaltic contractions 
grind down solid food so that it can be passed out the pylorus. With 
impaired gastric accommodation, there is increased pressure in the 
upper stomach after meal ingestion compromising the ability of the 
upper stomach to act as a reservoir for ingested food.9, 10 Impaired 
accommodation has shown to be associated with ES and weight loss in 
patients with functional dyspepsia.10 Impaired proximal gastric func-
tion has also been described in patients with idiopathic gastropare-
sis11: 25 of 58 patents (43%) patients with gastroparesis had impaired 
accommodation using a gastric barostat, and this was associated with 
higher prevalence of ES and weight loss.
Postprandial fullness has been associated with delayed gastric 
emptying which is primarily due to impaired antral function. While 
smaller studies have found inconsistent associates of symptoms to 
delayed gastric emptying, larger scale studies often report association 
of delayed gastric emptying with increased severity of PPF, nausea, 
and vomiting.12 For examples, in two studies (one of 343 patients and 
another of 392 patients with functional dyspepsia seen in referral cen-
ters), the symptoms of PPF and vomiting were associated with delayed 
gastric emptying of solids.13, 14
Thus, EF and PPF appear to be important symptoms in patients 
with gastroparesis. The attributes and importance of these symptoms 
and effects on patients have not been specifically characterized. The 
aims of this study were to characterize ES and PPF in patients with 
gastroparesis. We wanted to assess relationships of ES and PPF with 
etiology of gastroparesis, quality of life, body weight, gastric emptying, 
and water load testing.
2  | METHODS
2.1 | Overview
The NIDDK Gastroparesis Clinical Research Consortium (GpCRC) is 
a cooperative network of eight academic motility centers and one 
Data Coordinating Center (DCC) funded through the NIDDK of the 
National Institutes of Health (NIH).15,16 The Gastroparesis Registry 2 
(ClinicalTrials.gov Identifier: NCT NCT01696747) was implemented 
as an observational study of patients with gastroparesis enrolled pro-
spectively. This study uses data from the second gastroparesis reg-
istry (GpR2) of the NIDDK GpCRC. GpR2 was designed, in part, to 
enhance the understanding of symptoms and physiologic dysfunction 
in patients with gastroparesis. Physiologic testing included measuring 
gastric emptying of liquids in the presence of solids, and performing 
a water load test.
This report focuses on patients with either idiopathic or diabetic 
gastroparesis. The diabetic patients could have either Type 1 diabe-
tes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) as defined 
by the patient and their physician. The diagnosis of patients with the 
idiopathic etiology was based on no previous gastric surgery, no dia-
betes history (before or after the onset of gastroparesis at enrollment), 
a  normal hemoglobin A1C, and no other known etiologies.
All studies were approved by the Institutional Review Board at 
each Clinical Center and at the DCC. The authors had access to the 
study data and have reviewed and approved the final manuscript.
2.2 | Enrollment
Gastroparetic patients were enrolled at eight centers into the NIH 
Gastroparesis Registry from September 2012 to March 2016. 
Enrolled patients met specific entry criteria being 18 years or older 
with symptoms of at least 12 weeks duration, delayed gastric empty-
ing scintigraphy (GES) using the 4 hour Eggbeaters protocol (gastric 
retention >60% at 2 hours and/or >10% at 4 hours) within 6 months 
of enrollment, and no structural abnormality as seen by upper endos-
copy within 1 year of enrollment.
2.3 | Study protocol
During face- to- face interviews with each subject, the study physi-
cians or coordinators completed case report forms including data 
relating to gastroparesis disease onset, symptoms, disease profile, as-
sociated medical conditions, medication, and supplemental therapies. 
Study physicians performed a comprehensive physical examination. 
Key Points
● Early satiety (ES) and postprandial fullness (PPF) are often 
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Laboratory measures were obtained, including hemoglobin A1C val-
ues, antinuclear antibody (ANA), and erythrocyte sedimentation rate 
(ESR).
The clinical severity of gastroparesis was graded on a scale 
originally proposed by Abell et al. and reported in the American 
Neurogastroenterology and Motility Society (ANMS) review on treat-
ment of gastroparesis.17 The severity was graded as grade 1: mild gas-
troparesis (symptoms relatively easily controlled and able to maintain 
weight and nutrition on a regular diet); grade 2: compensated gast-
roparesis (moderate symptoms with only partial control with use of 
daily medications, able to maintain nutrition with dietary adjustments); 
grade 3: gastroparesis with gastric failure (refractory symptoms that 
are not controlled as shown by the patient having ER visits, frequent 
doctor visits or hospitalizations and/or inability to maintain nutrition 
via an oral route).
Each patient filled out the 20 item Patient Assessment of Upper 
Gastrointestinal Symptoms (PAGI- SYM) questionnaire which assesses 
symptoms of gastroparesis, dyspepsia, and gastroesophageal reflux 
disease18; it includes the nine symptoms of the GCSI which asks about 
nausea, retching, vomiting, stomach fullness, inability to finish meal, 
excessive fullness, loss of appetite, bloating, and abdominal disten-
sion.19 Early satiety was assessed using the phrase “Not able to finish 
a normal- sized meal (for a healthy person).” Postprandial fullness was 
assessed with the phrase “Feeling excessively full after meals.” The 
PAGI- SYM also inquires about symptoms of gastroesophageal reflux 
including daytime heartburn, heartburn lying down, daytime chest dis-
comfort, nighttime chest discomfort, daytime reflux, nighttime reflux, 
and bitter taste. In the PAGI- SYM, patients are asked to assess the 
severity of their symptoms during the previous 2 weeks using a 0- 5 
scale where no symptoms = 0, very mild = 1, mild = 2, moderate = 
3, severe = 4, and very severe = 5. The GCSI equals the mean of the 
nausea/vomiting subscore, PPF/ES subscore, and bloating subscore 
where: Nausea/vomiting subscore = mean of the scores for nausea, 
retching, and vomiting; PPF/ES sub- score = mean of the scores for 
stomach fullness, inability to finish meal, excessive fullness, and loss 
of appetite; and Bloating subscore = mean of the scores for bloating 
and large stomach.
Disease- specific quality of life was assessed by the Patient 
Assessment of Upper Gastrointestinal Disorders Quality of Life (PAGI- 
QOL) survey, which scores 30 factors from 0 (none of the time) to 5 (all 
of the time).20 Patients were asked how often gastrointestinal prob-
lems they may be experiencing have affected different aspects of their 
quality of life and well- being in the past 2 weeks. Overall PAGI- QOL 
scores were calculated by taking means of all subscores after reversing 
item scores; thus a mean PAGI- QOL score of 0 represents poor quality 
of life while 5 reflects the best life quality.
The Medical Outcomes Study 36- Item Short- Form Health Survey 
version 2 (SF- 36v2) was additionally used to assess the patients’ 
views of overall physical and mental health in the past 4 weeks.21 
The eight subscales were standardized to the 1998 U.S. general 
population with a mean (±SD) of 50±10. Physical and mental health 
summary measures were computed. A higher score reflects higher 
quality of life.
2.4 | Gastric emptying scintigraphy
Gastric emptying scintigraphy was performed using a low- fat, egg 
white meal with imaging at 0, 1, 2, 4 hours after meal ingestion, as 
described by a published multicenter protocol22 and endorsed by the 
Society of Nuclear Medicine and American Neurogastroenterology 
and Motility Society.23 This protocol ensures standardized informa-
tion about gastric emptying across sites. In addition, liquid gastric 
emptying in the presence of solids was assessed using Indium- 111.24
Patients were instructed to stop medications that could affect gas-
trointestinal motility for 48 hours prior to the study and to come to the 
Nuclear Medicine Section in the morning after fasting overnight, that 
is, an 8 hour fast. Gastric emptying scintigraphy was performed using 
a standard low- fat, Eggbeaters® meal to measure solid emptying.22, 23 
The meal consisted of the equivalent of two large eggs radiolabeled 
with Tc- 99m sulfur colloid served with two pieces of white bread and 
jelly. In addition, patients were given 120 mL water radiolabeled with 
In- 111 diethylene triamine pentacetic acid for the measurement of 
liquid gastric emptying. Following ingestion of the meal, imaging was 
performed at 0, 1, 2, and 4 hours with the patient upright for measur-
ing gastric emptying of Tc- labeled solids and 111- In- labeled liquids. In 
between imaging, patients generally sat in the nuclear medicine wait-
ing area.
Gastric emptying was analyzed as percent of radioactivity retained 
in the stomach over time using the geometric center of the decay- 
corrected anterior and posterior counts for each time point. Gastric 
retention of Tc- 99m >60% at 2 hours and/or >10% at 4 hours was 
considered delayed gastric emptying of solids. Delayed gastric emp-
tying was graded according to the gastric retention at 4 hours: mild 
(≤20% gastric retention at 4 hours), moderate (>20- 35%), and severe 
(>35%).23 Delayed gastric emptying of liquids in the presence of solids 
is greater than 50% retention of In- 111 at 1 hour emptying.24
2.5 | Water load satiety testing
A satiety test of non- caloric liquid water was performed at enrollment. 
The water load test is a standardized test to induce gastric distension 
and to evoke gastric motility responses without the complex hormo-
nal response of a caloric test meal. On the day of testing, patients 
reported after fasting overnight and were instructed to drink maxi-
mal volumes of water using an opaque 150 mL cup over 5 minutes 
until they felt completely full.25 The volume of water consumed was 
recorded.
2.6 | Statistical methods
Descriptive statistics (means, standard deviations, frequencies, and 
percentages) were used to compare subgroups of gastroparesis pa-
tients. Enrollment characteristics such as demographics, medical his-
tory, gastroparesis history, symptom severity, and quality of life were 
compared by etiology (idiopathic compared to diabetic). P- values 
were determined from Fisher’s exact tests for categorical variables 
and t tests for continuous variables. Enrollment characteristics were 
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TABLE  1 Characteristics of gastroparesis patients by early satiety severity
Characteristic
Not able to finish a normal size meal scorea
Total (n=198) P- valueb
None/very mild/
mild (n=53)
Moderate 
(n=46)
Severe/very  
severe (n=99)
Etiology
Idiopathic 34 (64.2%) 31 (67.4%) 69 (69.7%) 134 (67.7%) .49
Diabetic 19 (35.9%) 15 (32.6%) 30 (30.3%) 64 (32.3%)
Type 1 11 (57.9%) 9 (60.0%) 19 (63.3%) 39 (60.9%) .70
Type 2 8 (42.1%) 6 (40.0%) 11 (36.7%) 25 (39.1%)
Demographics
Gender: females 44 (83.0%) 41 (89.1%) 84 (84.9%) 169 (85.4%) .86
Age (years) 47.7±13.8 43.6±13.2 42.2±12.3 44.0±13.1 .02
Hispanic 9 (17.0%) 10 (21.7%) 11 (11.1%) 30 (15.2%) .24
Race: white 49 (92.5%) 41 (89.1%) 87 (87.9%) 177 (89.4%) .39
Gastroparesis history
Nature of gastroparesis symptoms
Chronic, but stable 11 (20.8%) 13 (28.3%) 10 (10.2%) 34 (17.3%) .54
Chronic, but progressive worsening 4 (7.6%) 6 (13.0%) 28 (28.6%) 38 (19.3%)
Chronic, but some improvement 7 (13.2%) 6 (13.0%) 9 (9.2%) 22 (11.2%)
Chronic with periodic exacerbations 17 (32.1%) 14 (30.4%) 35 (35.7%) 66 (33.5%)
Cyclic pattern 12 (22.6%) 7 (15.2%) 16 (16.3%) 35 (17.8%)
Asymptomatic 2 (3.8%) 0 (0.0%) 0 (0.0%) 2 (1.0%)
Gastroparesis severity
Mild (grade 1) 20 (37.7%) 8 (17.4%) 10 (10.2%) 38 (19.3%) <.0001
Compensated (grade 2) 29 (54.7%) 34 (73.9%) 70 (71.4%) 133 (67.5%)
Gastric failure (grade 3) 4 (7.6%) 4 (8.7%) 18 (18.4%) 26 (13.2%)
Medical history
BMI (kg/m2) 29.2±8.0 28.1±6.1 26.1±7.1 27.4±7.2 .009
Weight change (kg) from start of gastroparesis 0.9±31.3 4.7±37.7 −3.3±32.1 −0.3±33.3 .64
Weight change from start of gastroparesis
Increased 22 (41.5%) 29 (63.0%) 42 (42.4%) 93 (47.0%) .77
Decreased 30 (56.6%) 14 (30.4%) 54 (54.6%) 98 (49.5%)
Same 1 (1.9%) 3 (6.5%) 3 (3.0%) 7 (3.5%)
Weight change in last 6 months
Increased 20 (37.7%) 17 (37.0%) 28 (28.3%) 65 (32.8%) .47
Decreased 20 (37.7%) 19 (41.3%) 48 (48.5%) 87 (43.9%)
Same 13 (24.5%) 10 (21.7%) 23 (23.2%) 46 (23.2%)
Use of prokinetics 16 (30.2%) 14 (30.4%) 36 (36.4%) 66 (33.3%) .41
Use of antiemetics 44 (83.0%) 36 (78.3%) 79 (79.8%) 159 (80.3%) .68
Use of narcotics 19 (35.9%) 16 (34.8%) 36 (36.4%) 71 (35.9%) .93
Laboratory results
HbA1c, if diabetic (%) 8.6±1.9 7.7±2.0 8.6±1.9 8.4±1.9 .80
HbA1c ≥8.0%, if diabetic 11 (57.9%) 6 (40.0%) 18 (60.0%) 33 (55.0%) .77
ANA negative, if idiopathic 26 (76.5%) 27 (87.1%) 62 (89.9%) 115 (85.8%) .08
ESR, if idiopathic 14.0±11.1 17.0±12.1 13.5±12.0 14.5±11.8 .46
ESR elevated >30 mm, if idiopathic 4 (11.8%) 4 (12.9%) 6 (9.0%) 14 (10.6%) .61
(continues)
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Characteristic
Not able to finish a normal size meal scorea
Total (n=198) P- valueb
None/very mild/
mild (n=53)
Moderate 
(n=46)
Severe/very  
severe (n=99)
PAGI- SYM symptom severity (0- 5)c
Nausea/vomiting sub- score 1.3±1.3 1.6±1.3 2.3±1.3 1.9±1.4 <.001
Satiety/fullness sub- score 1.8±1.0 3.0±0.6 4.2±0.6 3.3±1.2 <.001
Stomach fullness score 2.4±1.3 3.3±1.1 4.1±0.8 3.5±1.3 <.001
Not able to finish a normal- sized meal score 1.2±0.8 3.0±0.0 4.6±0.5 3.3±1.6 <.001
Feeling excessively full after meals score 2.2±1.4 3.5±0.9 4.5±0.6 3.6±1.4 <.001
Loss of appetite score 1.4±1.4 2.4±1.2 3.6±1.3 2.7±1.6 <.001
Bloating sub- sore 1.8±1.5 2.9±1.5 3.7±1.4 3.0±1.7 <.001
Cardinal symptom index (GCSI) 1.6±0.9 2.5±0.9 3.4±0.7 2.7±1.1 <.001
Upper abdominal pain sub- score 2.0±1.6 2.5±1.3 3.4±1.3 2.8±1.5 <.001
GERD sub- score 1.3±1.3 2.0±1.4 2.0±1.4 1.8±1.4 .006
Constipation score 1.7±1.7 2.6±1.8 3.1±1.7 2.6±1.8 <.001
PAGI- QOL (0- 5)d
Activity sub- score 3.0±1.2 2.9±1.1 2.4±1.2 2.7±1.2 .001
Clothing sub- score 3.4±1.6 2.9±1.7 2.7±1.8 2.9±1.8 .02
Diet sub- score 2.3±1.6 2.0±1.2 1.4±1.1 1.8±1.3 <.001
Relationship sub- score 3.5±1.4 3.2±1.4 3.2±1.3 3.3±1.3 .16
Psychology sub- score 3.1±1.4 3.1±1.4 3.1±1.4 3.1±1.4 .70
Total PAGI- QOL 3.1±1.2 2.8±1.1 2.5±1.0 2.8±1.1 .005
SF- 36v2 Health Survey (past 4 weeks)e
Physical health summary measure 36.6±11.0 35.8±10.5 30.7±9.5 33.5±10.5 .001
Mental health summary measure 41.5±12.6 41.9±13.3 41.6±13.8 41.6±13.3 .99
PHQ- 15
PHQ- 15 total score 13.0±5.2 14.9±4.4 14.9±4.6 14.4±4.8 .04
No/low somatization 15 (28.3%) 5 (10.9%) 15 (15.2%) 35 (17.7%) .03
Medium somatization 16 (30.2%) 19 (41.3%) 27 (27.3%) 62 (31.3%)
High somatization 22 (41.5%) 22 (47.8%) 57 (57.6%) 101 (51.0%)
Solid gastric scintigraphy
Percent retention at 1 hour 83.0±11.6 78.9±15.3 80.4±12.3 80.7±12.9 .22
Percent retention at 2 hours 65.7±17.6 62.4±15.5 65.2±17.3 64.7±16.9 .96
Percent retention at 4 hours 26.1±19.2 28.8±15.4 33.9±21.3 30.6±19.7 .01
Liquid gastric scintigraphy
Percent retention at 30 minutes 60.0±14.1 62.2±16.9 67.0±17.9 64.4±17.0 .07
Percent retention at 1 hour 47.5±15.3 48.0±17.9 51.6±17.4 49.8±17.0 .22
Water load test
Total volume of water consumed (mL) 472±278 335±143 326±174 368±211 .001
Total volume of water consumed if completely full (mL) 511±309 338±132 318±182 370±225 .001
Data are means±standard deviations or number (percents).
aNausea severity is a score from the Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI- SYM).
bThe significance of difference in binary variables between groups was tested with a Cochran- Armitage trend test, the significance of difference in categor-
ical variables between groups was tested with a Mantel- Haenszel chi- squared test, and the significance of difference in continuous variables between 
groups was tested with a non- parametric Cuzick test for trend. All P- values are two- sided.
cSubscales derived from the Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI- SYM). A higher score reflects a greater 
severity.
dSubscales derived from the Patient Assessment of Upper Gastrointestinal Disorders- Quality of Life (PAGI- QOL). Scales have been recoded so that a higher 
score reflects a higher QOL.
eScores on the Medical Outcomes Study 36- Item Short- Form Health Survey V2 (SF- 36v2) standard recall were normalized to the 1998 U.S. general popu-
lation with a mean (±SD) of 50±10. A higher score reflects higher QOL or better health outcome.
TABLE  1  (continued)
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also compared by the subgroups of ES severity score and PPF on the 
PAGI- SYM instrument (none/very mild/mild, moderate, and severe/
very severe). P- values were determined from a Cochran- Armitage 
test for trend in ES or PPF subgroups for binary variables, a Mantel- 
Haenszel chi- squared test for trend in ES or PPF subgroups for cat-
egorical variables, and a non- parametric Cuzick test for trend in ES 
or PPF subgroups for continuous variables.26 Multiple logistic mod-
els were selected based on Akaike Information criteria using forward 
selection of all possible models derived from a candidate set of 16 
enrollment variables.27, 28 The resulting model for severe ES included 
etiology, age, solid gastric emptying percent at 4 hours, PAGI- SYM 
satiety/fullness sub- score, SF- 36 mental score, SF- 36 physical score, 
and PAGI- QOL score. The resulting model for severe PPF included 
etiology, age, race (white vs non- white), PAGI- QOL score, HbA1c%, 
and the following PAGI- SYM measures: satiety/fullness sub- score, 
bloating sub- score, and GERD sub- score. All P- values are two- sided; 
values <.05 were considered statistically significant. Analyses were 
performed using methods described in SAS version 9.3 (SAS Institute) 
or Stata version 13.1 (StataCorp).29
3  | RESULTS
3.1 | Patient characteristics
198 patients with gastroparesis were evaluated: 134 patients with 
idiopathic gastroparesis and 64 patients with diabetic gastroparesis 
(39 T1DM and 25 T2DM). Average age was 44.0±13.1 years. Females 
comprised the majority of patients (85.4%). Table 1 contains other 
Characteristic
Idiopathic 
(n=134) Diabetic (n=64)
Total 
(n=198) P- value
Satiety/fullness sub- score 3.2±1.2 3.4±1.2 3.3±1.2 .44
<3 46 (34.3%) 20 (31.3%) 66 (33.3%) .75
3- 3.75 35 (26.1%) 20 (31.3%) 55 (27.8%)
≥4 53 (39.6%) 24 (37.5%) 77 (38.9%)
Stomach fullness 3.4±1.3 3.6±1.2 3.5±1.3 .21
None- mild 29 (21.6%) 9 (14.1%) 38 (19.2%) .42
Moderate 38 (28.4%) 18 (28.1%) 56 (28.3%)
Severe- very severe 67 (50.0%) 37 (57.8%) 104 (52.5%)
Not able to finish a normal- sized 
meal
3.3±1.5 3.2±1.6 3.3±1.6 .55
None- mild 34 (25.4%) 19 (29.7%) 53 (26.8%) .78
Moderate 31 (23.1%) 15 (23.4%) 46 (23.2%)
Severe- very severe 69 (51.5%) 30 (46.9%) 99 (50.0%)
Feeling excessively full after meals 3.5±1.3 3.8±1.4 3.6±1.4 .21
None- mild 25 (18.7%) 8 (12.5%) 33 (16.7%) .25
Moderate 34 (25.4%) 12 (18.8%) 46 (23.2%)
Severe- very severe 75 (56.0%) 44 (68.8%) 119 (60.1%)
Loss of appetite 2.6±1.6 2.9±1.6 2.7±1.6 .39
None- mild 57 (42.5%) 23 (35.9%) 80 (40.4%) .58
Moderate 32 (23.9%) 15 (23.4%) 47 (23.7%)
Severe- very severe 45 (33.6%) 26 (40.6%) 71 (35.9%)
Water load test
Total volume of water consumed 
(mL)
354±210 397±213 368±211 .18
Total volume of water consumed 
if completely full (mL)
362±227 388±221 370±225 .51
Solid gastric scintigraphy
Percent retention at 1 hour 80.4±13.3 81.5±12.1 80.7±12.9 .56
Percent retention at 2 hours 64.1±16.0 65.8±18.9 64.7±16.9 .51
Percent retention at 4 hours 26.9±16.8 38.4±22.9 30.6±19.7 .0001
Liquid gastric scintigraphy
Percent retention at 30 minutes 62.6±17.0 67.9±16.7 64.4±17.0 .17
Percent retention at 1 hour 49.6±16.4 50.2±18.3 49.8±16.9 .88
TABLE  2 Satiety/fullness sub- score and 
components distributions by idiopathic and 
diabetic gastroparesis
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demographic information. The average GCSI score was of moderate 
severity (2.7±1.1). The majority of patients had compensated (grade 
2) gastroparesis (67.5%) with 13.2% of patients were graded as having 
gastric failure. At the time of enrollment in the registry, the predomi-
nant symptoms were nausea in 27.3% of patients, upper abdominal 
pain in 12.7% and vomiting in 5.5% of patients. Overall, the gastric 
emptying was moderately delayed with 30.6% retention at 4 hours, 
being more delayed in diabetic gastroparesis (38.4% retention) than 
idiopathic gastroparesis (26.8% retention; P=.0001). For the diabetic 
patients, the average HgbA1c was 8.4±1.9% with 55.0% of the dia-
betic patients having HgbA1c ≥8.0%. There was a decreased quality 
of life in the patients with gastroparesis most prominently with the 
SF- 36 physical score being 33.5 compared to normal of 50.
3.2 | Early satiety
Early satiety was severe or very severe in 99 of 198 (50%) patients 
(Table 1). Increasing severity of ES was associated with increasing gas-
troparesis severity (P<.0001). Increasing severity of ES was associated 
with other gastroparesis symptoms including nausea/vomiting subscore, 
satiety/early fullness subscore, bloating subscore, and individual symp-
tom severity scores for PPF, loss of appetite and upper abdominal pain, 
and GERD subscore. Increasing severity of ES was associated with de-
creased BMI (P=.009), decreased quality of life from PAGI- QOL (P=.005) 
and SF- 36 physical health (P=.001). Increasing severity of ES was associ-
ated with increasing gastric retention of a solid meal at 4 hours (P=.01) 
and decrease in volume consumed during the water load test (P=.001).
Severity scores for ES were similar between idiopathic and diabetic 
gastroparesis (3.3 vs 3.2) (Table 2). Other symptoms such as loss of ap-
petite and stomach fullness and the GCSI subscore for satiety/fullness 
were similar between idiopathic and diabetic gastroparesis.
Logistic regression analysis showed that severe/very severe ES 
was associated with increasing bloating subscore (P<.001), increas-
ing upper abdominal pain subscore (P=.002), and SF- 36 mental com-
ponent (P=.02), and increased GE retention at 4 hours (P=.007), and 
 decreased BMI (P=.001) (Table 3).
3.3 | Postprandial fullness
Postprandial fullness was severe or very severe in 119 of 198 (60%) 
patients (Table 4). Increasing severity of PPF was associated with 
other gastroparesis symptoms including nausea/vomiting subscore, 
satiety/early fullness subscore, and bloating subscore and individual 
symptoms of ES, loss of appetite, upper abdominal pain, and GERD 
subscore. Increasing severity of PPF was associated with gastropa-
resis severity (P=.003), decreased quality of life from PAGI- QOL 
(P=.006) and SF- 36 physical health (P=.006), but not body weight 
(P=.30). Increasing severity of PPF was associated with increasing gas-
tric retention of a solid meal at 4 hours (P=.01) and a decrease in the 
volume consumed during the water load test (P=.01).
Severity scores for PPF (3.5 vs 3.8) were similar between idiopathic 
and diabetic gastroparesis (Table 2).
Logistic regression analysis showed that severe/very severe PPF was 
associated with retching severity (P=.01), bloating subscore (P<.001), 
upper abdominal pain subscore (P=.001), and decreased BMI (Table 5).
4  | DISCUSSION
This study shows that ES and PPF are common symptoms in gastropa-
resis, both in diabetic and idiopathic gastroparesis. Many patents have 
severe or very severe ES (50% of patients) and PPF (60% of patients). 
TABLE  3 Logistic regression analyses of baseline predictors on severe early satietya in idiopathic and diabetic gastroparetics (n=196)
Baseline characteristic
Unadjusted analyses Adjusted analysis
OR (CI) Pb OR (CI) Pc
Etiology (diabetic vs idiopathic) 0.83 (0.46, 1.51) .54 0.47 (0.19, 1.18) .11
Gender (female vs male) 0.92 (0.42, 2.03) .84 0.29 (0.10, 0.88) .03
BMI (kg/m2) 0.95 (0.91, 0.99) .01 0.91 (0.86, 0.96) .001
PAGI- SYM, nausea score 1.63 (1.32, 2.00) <.001 1.24 (0.93, 1.67) .14
PAGI- SYM, vomiting score 1.36 (1.14, 1.63) .001 1.28 (0.98, 1.68) .07
PAGI- SYM, bloating score 1.75 (1.42, 2.16) <.001 1.98 (1.48, 2.64) <.001
PAGI- SYM, upper abdominal pain sub- score 1.83 (1.46, 2.29) <.001 1.55 (1.17, 2.07) .002
PAGI- SYM, GERD sub- score 1.19 (0.97, 1.46) .10 0.77 (0.57, 1.03) .08
SF- 36, mental score 1.00 (0.98, 1.02) .96 1.03 (1.01, 1.05) .02
Solid gastric scintigraphy, percent retention at 4 hours 1.02 (1.00, 1.03) .02 1.03 (1.00, 1.05) .007
aSevere early satiety defined as “severe” or “very severe” inability to finish a normal- sized meal score on the PAGI- SYM instrument.
bUnadjusted odds ratios, 95% confidence limits, P- values determined from logistic regression models of severe early satiety on each predictor.
cAdjusted odds ratios, 95% confidence limits, P- values were determined from a multiple logistic regression analyses of severe early satiety using all baseline 
predictors indicated. This model was determined from Akaike Information criteria (AIC) best subsets variable selection using a candidate set of baseline 
variables: gender, age at enrollment, etiology, race, BMI, SF- 36 physical score, SF- 36 mental score, PAGI- QOL total score, solid GES 2 hour retention per-
cent, solid GES 4 hour retention percent, and the following PAGI- SYM items: nausea score, vomiting score, retching score, bloating score, stomach visibly 
larger score, upper abdominal pain sub- score, and GERD sub- score.
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TABLE  4 Characteristics of gastroparesis patients by postprandial fullness severity
Characteristic
Excessively full after meals scorea
Total (n=198) P- valueb
None/very mild/
mild (n=33)
Moderate 
(n=46)
Severe/very 
severe (n=119)
Etiology
Idiopathic 25 (75.8%) 34 (73.9%) 75 (63.0%) 134 (67.7%) .10
Diabetic 8 (24.2%) 12 (26.1%) 44 (37.0%) 64 (32.3%)
Type 1 5 (62.5%) 6 (50.0%) 28 (63.6%) 39 (60.9%) .70
Type 2 3 (37.5%) 6 (50.0%) 16 (36.4%) 25 (39.1%)
Demographics
Gender: females 26 (78.8%) 40 (87.0%) 103 (86.6%) 169 (85.4%) .34
Age (years) 44.2±15.1 44.7±13.3 43.7±12.4 44.0±13.1 .86
Hispanic 4 (12.1%) 7 (15.2%) 19 (16.0%) 30 (15.2%) .61
Race: white 30 (90.9%) 41 (89.1%) 106 (89.1%) 177 (89.4%) .79
Gastoparesis history
Nature of gastroparesis symptoms
Chronic, but stable 7 (21.2%) 15 (32.6%) 12 (10.2%) 34 (17.3%) .98
Chronic, but progressive worsening 2 (6.1%) 4 (8.7%) 32 (27.1%) 38 (19.3%)
Chronic, but some improvement 6 (18.2%) 5 (10.9%) 11 (9.3%) 22 (11.2%)
Chronic with periodic exacerbations 10 (30.3%) 13 (28.3%) 43 (36.4%) 66 (33.5%)
Cyclic pattern 7 (21.2%) 8 (17.4%) 20 (17.0%) 35 (17.8%)
Asymptomatic 1 (3.0%) 1 (2.1%) 0 (0.0%) 2 (1.0%)
Gastroparesis severity
Mild (grade 1) 11 (33.3%) 12 (26.1%) 15 (12.7%) 38 (19.3%) .003
Compensated (grade 2) 18 (54.6%) 33 (71.7%) 82 (69.5%) 133 (67.5%)
Gastric failure (grade 3) 4 (12.1%) 1 (2.2%) 21 (17.8%) 26 (13.2%)
Medical history
BMI (kg/m2) 26.8±6.3 29.7±8.1 26.7±7.0 27.4±7.2 .30
Weight change (kg) from start of gastroparesis 0.0±23.0 8.4±41.3 −3.8±31.8 −0.3±33.3 .41
Weight change from start of gastroparesis
Increased 15 (45.5%) 25 (54.4%) 53 (44.5%) 93 (47.0%) .95
Decreased 16 (48.5%) 19 (41.3%) 63 (52.9%) 98 (49.5%)
Same 2 (6.1%) 2 (4.4%) 3 (2.5%) 7 (3.5%)
Weight change in last 6 months
Increased 11 (33.3%) 18 (39.1%) 36 (30.3%) 65 (32.8%) .97
Decreased 12 (36.4%) 19 (41.3%) 56 (47.1%) 87 (43.9%)
Same 10 (30.3%) 9 (19.6%) 27 (22.7%) 46 (23.2%)
Use of prokinetics 10 (30.3%) 19 (41.3%) 37 (31.1%) 66 (33.3%) .74
Use of antiemetics 28 (84.9%) 36 (78.3%) 95 (79.8%) 159 (80.3%) .63
Use of narcotics 12 (36.4%) 15 (32.6%) 44 (37.0%) 71 (35.9%) .82
Laboratory results
HbA1c, if diabetic (%) 9.6±1.9 7.1±1.1 8.5±1.9 8.4±1.9 .72
HbA1c ≥8.0%, if diabetic 7 (87.5%) 2 (16.7%) 26 (59.1%) 35 (54.7%) .81
ANA negative, if idiopathic 21 (84.0%) 29 (85.3%) 65 (86.7%) 115 (85.8%) .73
ESR, if idiopathic 11.2±9.6 17.6±12.4 14.1±12.0 14.5±11.8 .72
ESR elevated >30 mm, if idiopathic 2 (8.0%) 4 (11.8%) 8 (11.0%) 14 (10.6%) .74
(continues)
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Characteristic
Excessively full after meals scorea
Total (n=198) P- valueb
None/very mild/
mild (n=33)
Moderate 
(n=46)
Severe/very 
severe (n=119)
PAGI- SYM symptom severity (0- 5)c
Nausea/vomiting sub- score 1.1±1.2 1.6±1.3 2.2±1.3 1.9±1.4 <.001
Satiety/fullness sub- score 1.3±0.8 2.7±0.6 4.0±0.7 3.3±1.2 <.001
Stomach fullness score 1.7±0.9 3.0±1.0 4.1±0.8 3.5±1.3 <.001
Not able to finish a normal- sized meal score 1.3±1.0 2.7±1.2 4.1±1.1 3.3±1.6 <.001
Feeling excessively full after meals score 1.2±0.9 3.0±0.0 4.5±0.5 3.6±1.4 <.001
Loss of appetite score 1.2±1.4 2.2±1.2 3.4±1.4 2.7±1.6 <.001
Bloating sub- sore 1.3±1.3 2.7±1.5 3.5±1.5 3.0±1.7 <.001
Cardinal symptom index (GCSI) 1.3±0.7 2.3±0.9 3.3±0.8 2.7±1.1 <.001
Upper abdominal pain sub- score 1.3±1.2 2.4±1.5 3.4±1.3 2.8±1.5 <.001
GERD sub- score 1.2±1.1 1.8±1.3 2.0±1.4 1.8±1.4 .003
Constipation score 1.1±1.4 2.5±1.8 3.0±1.7 2.6±1.8 <.001
PAGI- QOL (0- 5)d
Activity sub- score 3.1±1.3 2.9±1.1 2.5±1.2 2.7±1.2 .004
Clothing sub- score 3.5±1.5 2.9±1.8 2.8±1.8 2.9±1.8 .05
Diet sub- score 2.4±1.6 2.0±1.3 1.6±1.2 1.8±1.3 .003
Relationship sub- score 3.7±1.3 3.2±1.4 3.2±1.3 3.3±1.4 .07
Psychology sub- score 3.5±1.3 3.0±1.4 3.0±1.4 3.1±1.4 .10
Total PAGI- QOL 3.2±1.2 2.8±1.1 2.6±1.1 2.8±1.1 .006
SF- 36v2 Health Survey (past 4 weeks)e
Physical health summary measure 39.5±10.9 32.5±10.7 32.2±9.8 33.5±10.5 .006
Mental health summary measure 43.2±12.6 42.1±13.2 41.0±13.6 41.6±13.3 .37
PHQ- 15
PHQ- 15 total score 12.0±5.9 15.2±4.3 14.7±4.5 14.4±4.8 .02
No/low somatization 13 (39.4%) 6 (13.0%) 16 (13.4%) 35 (17.7%) .004
Medium somatization 11 (33.3%) 12 (26.1%) 39 (32.8%) 62 (31.3%)
High somatization 9 (27.3%) 28 (60.9%) 64 (53.8%) 101 (51.0%)
Solid gastric scintigraphy
Percent retention at 1 hour 83.0±9.6 79.8±17.4 80.4±11.7 80.7±12.9 .33
Percent retention at 2 hours 64.3±16.3 65.5±16.6 64.4±17.4 64.7±16.9 .87
Percent retention at 4 hours 23.9±18.7 30.0±16.9 32.7±20.6 30.6±19.7 .01
Liquid gastric scintigraphy
Percent retention at 30 minutes 62.1±15.1 58.2±17.9 66.5±17.1 64.4±17.0 .14
Percent retention at 1 hour 50.4±17.1 48.0±15.2 50.3±17.6 49.8±16.9 .84
Water load test
Total volume of water consumed (mL) 457±258 372±221 341±186 368±211 .01
Total volume of water consumed if completely full 
(mL)
476±287 393±235 335±194 370±225 .01
Data are means±standard deviations or number (percents).
aNausea severity is a score from the Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI- SYM).
bThe significance of difference in categorical variables between groups was tested with Fisher’s exact test or chi- squared test. Continuous variables were 
analyzed with ANOVA. All P- values are two- sided.
cSubscales derived from the Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI- SYM). A higher score reflects a greater 
severity.
dSubscales derived from the Patient Assessment of Upper Gastrointestinal Disorders- Quality of Life (PAGI- QOL). Scales have been recoded so that a higher 
score reflects a higher QOL.
eScores on the Medical Outcomes Study 36- Item Short- Form Health Survey V2 (SF- 36v2) standard recall were normalized to the 1998 U.S. general popu-
lation with a mean (±SD) of 50±10. A higher score reflects higher QOL or better health outcome.
TABLE  4  (continued)
     |  9 of 11PARKMAN et Al.
Early satiety and PPF severity are associated with other measures of 
gastroparesis severity including overall gastroparesis severity, body 
weight, quality of life, gastric emptying, water load testing. These 
characteristics of ES and PPF to gastroparesis severity, quality of life, 
and physiologic abnormalities make ES and PPF important symptoms 
characterizing gastroparesis.
Gastric accommodation as assessed by barostat or SPECT scan-
ning, have been correlated with the symptom of ES.11, 30 The water load 
test was used in this multicenter study as a satiety test of a non- caloric 
water liquid meal.25 This standardized test induces gastric distension 
and evokes gastric motility responses without the complex hormonal 
response of a caloric test meal. Prior studies have shown that patients 
with functional dyspepsia ingested smaller volumes of water than nor-
mal controls (358 mL vs 557 mL).25 Our patients with gastroparesis 
ingested on average low volumes of water (368 mL). Our study shows 
that increasing symptoms of ES and PPF are objectively associated 
with decreased volume consumed during the water load test.
The symptoms of ES and PPF are both associated with delayed 
gastric emptying. Increasing severity of ES and PPF are associated 
with increased gastric retention at 4 hours. In multivariate analysis, 
ES but not PPF was associated with impaired gastric emptying. Other 
studies have been able to relate nausea, vomiting, and PPF to delayed 
gastric emptying.12
Functional dyspepsia is diagnosed by having symptoms of PPF, 
early satiation, epigastric pain/burning. Symptoms of gastropare-
sis overlap with those of functional dyspepsia. This is not surprising 
since one (gastroparesis) involves gastric symptoms with objective 
delay in gastric emptying, whereas the other (functional dyspepsia) 
is a symptom only based disorder. Our gastroparesis consortium has 
shown that nearly 85% of gastroparesis patients meet the definition 
of functional dyspepsia, primarily postprandial distress syndrome 
(PDS).15 Early satiety and PPF are also prevalent in patients with the 
PDS form of functional dyspepsia, since in PDS, meal ingestion trig-
gers symptoms.31
Early satiety and PPF symptoms appear to capture different patho-
physiologic aspects of gastroparesis: ES - impaired proximal gastric 
(fundic) function and PPF - impaired distal gastric (antral) function. 
This study shows that the characteristics of ES overlap with PPF. The 
presence of ES vs PPF does not differentiate between other symptoms 
in gastroparesis. Early satiety and PPF severity are significantly asso-
ciated with other gastroparesis symptoms including nausea/vomiting 
subscore and bloating subscore and measures of gastroparesis sever-
ity, and quality of life, gastric emptying, water load testing. On multi-
variable analysis, significant relationships were found between ES with 
bloating and upper abdominal pain and between PPF with retching, 
stomach distension, and upper abdominal pain. Pathophysiologically, 
both ES and PPF are related to delayed gastric emptying and impair-
ments of the water load test. Although on multivariate analysis, ES but 
not PPF was associated with impaired gastric emptying. It is perhaps 
not surprising that the severity of ES is associated with PPF: with ES, 
the patients becomes full early with eating, this fullness may persist 
after eating leading to PPF. These two symptoms of ES and PPF may 
not be reliably distinguished by patients. In a recent study that looked 
at quality of life in gastroparesis patients,32 four of the five symptoms 
suggested by the FDA guidance document of gastroparesis5 were 
significantly related to impaired QOL, namely, nausea, vomiting, ES, 
and upper abdominal pain. Interestingly, PPF was not an independent 
predictor of QOL physical health. This suggests that, of the two symp-
toms, ES might be the preferable symptom to ask about.
In summary, the results of this study bring to forefront the notion 
that ES and PPF are common symptoms in gastroparesis that often 
judged by the patients to be severe. Early satiety and PPF severity are 
TABLE  5 Logistic regression analyses of 
baseline predictors on severe postprandial 
fullnessa in idiopathic and diabetic 
gastroparetics (n=198)
Baseline characteristic
Unadjusted analyses Adjusted analyses
OR (CI) Pb OR (CI) Pc
Etiology (diabetic vs idiopathic) 1.73 (0.92, 3.25) .09 2.13 (0.92, 4.91) .08
BMI (kg/m2) 0.97 (0.93, 1.00) .08 0.94 (0.89, 0.99) .01
PAGI- SYM, nausea score 1.54 (1.27, 1.88) <.001 2.15 (0.92, 5.06) .08
PAGI- SYM, vomiting score 1.39 (1.14, 1.68) .001 1.09 (0.69, 1.73) .72
PAGI- SYM, retching score 1.28 (1.06, 1.55) .01 0.52 (0.31, 0.87) .01
PAGI- SYM, stomach visibly 
larger score
2.03 (1.60, 2.57) <.001 1.62 (1.28, 2.04) <.001
PAGI- SYM, upper abdominal 
pain sub- score
1.68 (1.40, 2.02) <.001 1.68 (1.27, 2.21) <.001
aSevere postprandial fullness defined as “severe” or “very severe” excessively full after meals score on 
the PAGI- SYM instrument.
bUnadjusted odds ratios, 95% confidence limits, P values determined from logistic regression models 
of severe fullness on each predictor.
cAdjusted odds ratios, 95% confidence limits, P values were determined from a multiple logistic regres-
sion analyses of severe fullness using all baseline predictors indicated. This model was determined 
from Akaike Information criteria (AIC) best subsets variable selection using a candidate set of baseline 
variables: gender, age at enrollment, etiology, race, BMI, SF- 36 physical score, SF- 36 mental score, 
PAGI- QOL total score, solid GES 2 hour retention percent, solid GES 4 hour retention percent, and the 
following PAGI- SYM items: nausea score, vomiting score, retching score, bloating score, stomach visi-
bly larger score, upper abdominal pain sub- score, and GERD sub- score.
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significantly associated with other measures of gastroparesis sever-
ity, and quality of life, gastric emptying, body weight, and water load 
testing. These relationships of ES and PPF to gastroparesis severity, 
quality of life, and gastric emptying make these important symptoms 
characterizing gastroparesis and important symptoms to follow in 
treating patients with gastroparesis.
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